Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 2/20 | 0.56 |
| ▸ | MMP9 | P14780 | 2/20 | 0.56 |
| ▸ | HTR6 | P50406 | 8/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.47 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.43 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.43 |
| ▸ | MMP3 | P08254 | 1/20 | 0.42 |
| ▸ | MMP8 | P22894 | 1/20 | 0.42 |
| ▸ | MMP13 | P45452 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3858590 | 0.87 | MMP2 (0.56) | MMP2MMP9HTR6MAPTKDM4E | |
| SCHEMBL3860728 | 0.84 | HTR6 (0.56) | MMP2MMP9HTR6MAPTKDM4E | |
| SCHEMBL3858525 | 0.81 | HTR6 (0.66) | MMP2MMP9HTR6MAPTDRD1 | |
| SCHEMBL3858764 | 0.80 | HTR6 (0.46) | MMP2MMP9HTR6MAPTKDM4E | |
| SCHEMBL3856630 | 0.79 | HTR6 (0.63) | MMP2MMP9HTR6MAPTDRD1 | |
| SCHEMBL29794093 | 0.78 | MMP2 (0.54) | MMP2MMP9HTR6MAPTALDH1A1 | |
| SCHEMBL18197230 | 0.78 | LMNA (0.61) | MMP2MMP9HTR6MAPTLMNA | |
| SCHEMBL4548022 | 0.78 | LMNA (0.61) | MMP2MMP9HTR6MAPTLMNA | |
| SCHEMBL842406 | 0.77 | PDK2 (0.59) | MAPTKDM4EALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL31397805 | 0.77 | PDK2 (0.59) | MAPTKDM4EALDH1A1CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1650190-A1 | 3-aryl-3-methyl-quinoline-2,4-diones, preparation method thereof and pharmaceutical composition containing same | Korea Research Institute of Chemical Technology (KR) | 2006-04-26 | — | — | EP | claimed |
| US-20060084676-A1 | 3-aryl--3-methyl-quinoline-2, 4-diones, preparation method thereof, and pharmaceutical composition containing the same | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2006-04-20 | — | — | US | claimed |
| US-7592457-B2 | 3-aryl-3-methyl-quinoline-2, 4-diones, preparation method thereof, and pharmaceutical composition containing the same | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2009-09-22 | — | — | US | disclosed |
| US-7592457-B2 | 3-aryl-3-methyl-quinoline-2, 4-diones, preparation method thereof, and pharmaceutical composition containing the same | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2009-09-22 | — | — | US | disclosed |
| US-7592457-B2 | 3-aryl-3-methyl-quinoline-2, 4-diones, preparation method thereof, and pharmaceutical composition containing the same | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2009-09-22 | — | — | US | disclosed |
| EP-1650190-A1 | 3-aryl-3-methyl-quinoline-2,4-diones, preparation method thereof and pharmaceutical composition containing same | Korea Research Institute of Chemical Technology (KR) | 2006-04-26 | — | — | EP | disclosed |
| US-20060084676-A1 | 3-aryl--3-methyl-quinoline-2, 4-diones, preparation method thereof, and pharmaceutical composition containing the same | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2006-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084676-A1 | 3-aryl--3-methyl-quinoline-2, 4-diones, preparation method thereof, and pharmaceutical composition containing the same | HTR6, HTR3B, HTR2C | MMP2 4749/4885MMP9 4831/4885HTR6 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.